Pure Global
NCT05831306

A Clinical Trial Evaluating Diets for IBS

A Randomized Clinical Trial Evaluating Two Different Diets for IBS
Beth Israel Deaconess Medical Center·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Irritable Bowel Syndrome
Drug/Device/Intervention
Diet A
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Beth Israel Deaconess Medical Center
Location
Boston,Ann Arbor, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jul 21, 2021
End date
Dec 31, 2023
Enrollment
60 participants
Primary outcome

Abdominal Pain Intensity

Summary

Diet and lifestyle changes are the recommended first line treatments for symptom relief in
 irritable bowel syndrome (IBS). Currently the only diet that is widely recommended and for
 which there is good evidence of efficacy in IBS is one low in fermentable oligosaccharides,
 disaccharides, monosaccharides, and polyols (low-FODMAP). While effective, the Low-FODMAP
 diet is burdensome and costly to patients and in clinical practice adherence to FODMAP
 restriction is less than optimal. Further, patients who respond to a FODMAP restriction often
 are reluctant to reintroduce more FODMAPs into their diet, which may deprive them of foods,
 particularly fruits and vegetables with important health benefits. Therefore, there is a need
 for other dietary interventions for IBS that are less burdensome to patients. This clinical
 trial assesses the efficacy of two dietary interventions.

ICD-10 classifications
Irritable bowel syndromeOther and unspecified irritable bowel syndromeIrritable bowel syndrome with mixed bowel habits [IBS-M]Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05831306
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05831306 through Pure Global AI's free database. This phase not specified trial is sponsored by Beth Israel Deaconess Medical Center and is currently Recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.